Exercise Detection Study
Type 1 Diabetes
About this trial
This is an interventional diagnostic trial for Type 1 Diabetes focused on measuring exercise, artificial pancreas, hypoglycemia, type 1 diabetes
Eligibility Criteria
TYPE 1 DIABETIC SUBJECT CRITERIA
Inclusion criteria:
- Male or female subjects 21 to 45 years of age with a diagnosis of T1D for at least 6 months on an insulin pump.
- Physically active on a regular basis, i.e. at least 3 days of scheduled physical activity per week and willing to perform approximately 60 minutes of exercise (as determined by the investigator after reviewing the subjects activity level).
- Willingness to follow all study procedures.
- Willingness to sign informed consent and HIPAA documents.
Exclusion criteria:
a. Pregnancy or Lactation: i. For women of childbearing potential, there is a requirement for a negative urine pregnancy test. b. Any cardiovascular disease, defined as a clinically significant EKG abnormality at the time of screening or any history of: stroke, heart failure, myocardial infarction, angina pectoris, or coronary arterial bypass graft or angioplasty. Diagnosis of 2nd or 3rd degree heart block or any non-physiological arrhythmia judged by the investigator to be exclusionary. c. Renal insufficiency (GFR < 60 ml/min, using the MDRD equation as report by the OHSU laboratory). d. Hematocrit of less than or equal to 34%. e. History of severe hypoglycemia during the past 12 months prior to screening visit or hypoglycemia unawareness as judged by the investigator. f. Adrenal insufficiency. g. Any active infection. h. Known or suspected abuse of alcohol, narcotics, or illicit drugs (except marijuana use).
i. Seizure disorder. j. Active foot ulceration. k. Severe peripheral arterial disease characterized by ischemic rest pain or severe claudication. l. Major surgical operation within 30 days prior to screening. m. Use of an investigational drug within 30 days prior to screening. n. Chronic usage of any immunosuppressive medication (such as cyclosporine, azathioprine, sirolimus, or tacrolimus). o. Bleeding disorder, treatment with warfarin, or platelet count below 50,000. p. Current administration of oral or parenteral corticosteroids. q. Any life threatening disease, including malignant neoplasms and medical history of malignant neoplasms within the past 5 years prior to screening (except basal and squamous cell skin cancer). r. Any concurrent illness, other than diabetes, that is not controlled by a stable therapeutic regimen. s. Beta blockers or non-dihydropyridine calcium channel blockers. t. A positive response to any of the questions from the Physical Activity Readiness Questionnaire, see Appendix A. u. Any chest discomfort with physical activity, including pain or pressure, or other types of discomfort. v. Any clinically significant disease or disorder which in the opinion of the Investigator may jeopardize the subject's safety or compliance with the protocol.
HEALTHY SUBJECT CRITERIA
Inclusion Criteria:
- Male or female subjects 21 to 45 years of age.
- Physically active on a regular basis, i.e. at least 3 days of scheduled physical activity per week and willing to perform approximately 60 minutes of exercise (as determined by the investigator after reviewing the subjects activity level).
- Willingness to follow all study procedures.
- Willingness to sign informed consent and HIPAA documents.
Exclusion criteria:
- Pregnancy or Lactation: For women of childbearing potential, there is a requirement for a negative urine pregnancy test.
- Any history or evidence of renal insufficiency, adrenal insufficiency, liver disease or anemia.
- A history of cerebrovascular disease or coronary artery disease (or angina) regardless of the time since occurrence.
- Congestive heart failure, New York Heart Association (NYHA) any class.
- Diagnosis of 1st, 2nd or 3rd degree heart block or any arrhythmia judged by the investigator to be exclusionary.
- Any condition which, in the opinion of the investigator, makes it difficult to engage in vigorous physical activity.
- Any active infection.
- Severe peripheral arterial disease characterized by ischemic rest pain or severe claudication.
- Active alcohol abuse, substance abuse, or severe mental illness (as judged by the principal investigator).
- Active malignancy, except basal cell or squamous cell skin cancers.
- Major surgical operation within 30 days prior to screening.
- Seizure disorder.
- Bleeding disorder, or treatment with warfarin.
- Use of any chronic medications.
- Use of an investigational drug within 30 days prior to screening.
- Any reason the principal investigator deems exclusionary.
Sites / Locations
- Oregon Health and Science University
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Aerobic First, Resistance Second
Resistance First, Aerobic Second
Subjects will complete three 15 minute periods of aerobic exercise, with 10 minute recovery between each period. This will be followed by 5-15 minute periods of up to 7 activities of daily living with an additional 20 minute period of resistance exercise, such as straight leg raises.
Subjects will complete 5-15 minute periods of up to 7 activities of daily living with an additional 20 minute period of resistance exercise, such as straight leg raises. This will be followed by three 15 minute periods of aerobic exercise, with 10 minute recovery between each period.